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 SYMPOSIUM: OPTIMISATION IN PROSTATE RADIO-
THERAPY – WHERE DO WE PUT OUR MONEY?  
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The main goal of research in the field of radiotherapy (RT) is to 
achieve maximum tumor control while sparing normal tissues. For this 
reason, reducing the uncertainties associated with treatment delivery 
is essential, as they affect the entire therapeutic process. 
Clinical uncertainties: The first uncertainty associated with RT is the 
need to deliver RT to patients with low-very-low risk disease and after 
surgery, i.e. to avoid excess RT in patients with clinically insignificant 
prostate cancer or in post-prostatectomy patients. Once an indication 
for RT is established, it is important to (1) identify the targets, (2) 
select neo-adjuvant and/or adjuvant therapies, and (3) select the 
total dose and daily fraction. Clinicians often overlook these factors as 
sources of uncertainty. For this reason, one of the major goals of 
future RT procedures and technologies should be to reduce the uncer-
tainty of identifying the extent and location of the tumor, and the 
potential radiosensitivity of the cancer cells and normal tissues. 
Further studies are needed to determine whether the prescribed dose 
levels might differ among various prognostic groups, if non-
homogeneous dose distributions are preferable for different radiosen-
sitive regions in the prostate, or if selective dose de-escalation is 
feasible in selected patients. 
Technical uncertainties: In the current scenario, any attempts to 
reduce the uncertainty of target localization for treatment delivery 
are well justified. Image-guided RT techniques allow the radiation 
oncologist to accurately localize the target tissue, which limits the 
uncertainty associated with setup errors, organ shape/filling (or 
voiding) variations, and inter-fraction organ movement. Accurate 
localization of the target helps to reduce the planned target volume 
(PTV) margins around the clinical target volume (CTV), to include a 
smaller volume of the rectum/bladder in the high-dose region, and to 
decrease the dose absorbed by the patient.These factors help to 
reduce the incidence of late RT-induced toxicities. 
To prevent target missing due to intra-fraction movements, several 
recent studies focused on four-dimensional RT, which improved the 
localization accuracy in all four dimensions (space+time).  
Extreme reduction of the CTV margins and further research to im-
prove existing technologies are expensive. For this reason, the clinical 
advantages, if any, of the dosimetric gains in the organs at risk must 
be determined. It must also be examined whether the margin reduc-
tions are beneficial for all patients or for selected patients, such as 
those harboring known clinical/geneticrisk factors. 
Patient-related uncertainties: The considerations described above 
have opened another major research field: the issue of reducing 
uncertainties in RT delivery while considering the cost of using these 
sophisticated techniques. We should encourage widespread collection 
of clinical data in relation to tumor control and RT-induced toxicity, 
ideally for all treated patients, and invest in data warehousing, data 
mining,and statistical analysis. Currently, <5% of patients are partici-
pating in clinical trials, so most patients could be included in such 
data collection. Increasing the number of databases focusing on 
patient factors, disease characteristics, and treatment options, will 
facilitate individualized and real-time prediction of desired outcomes. 
Availability of such databases, that allow the clinician to choose an 
optimal treatment based on known patient’s factors, might have 
significant advantages over existing prediction tools: similar patients 
can be grouped and easily found, with predictions updated in real 
time, overcoming the limitation of patient variability (e.g., stage 
migration) and changes in treatment options over time. 
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Up to 40% of patients with intermediate-risk prostate cancer will fail 
radical prostatectomy or precision image-guided radiotherapy (IGRT). 
Additional genetic prognosticators are needed to triage these patients 
towards intensified combination therapy with novel targeted thera-
peutics to improve both local and systemic control rates.  To address 
these questions, we are performing genomic analyses (for mutations 
and copy number alterations (CNAs) using comparative genomic 
hybridization and whole genome sequencing) of tumour DNA derived 
from frozen needle biopsies of 126 men with intermediate-risk disease 
who underwent image-guided radiotherapy (IGRT) to a mean dose of 
76.4Gy or men undergoing radical prostatectomy.   
Patients whose tumors had CNAs in both PTEN and c-MYC, NKX3.1 and 
StAR/HSD17B2 had significantly increased genetic instability (percent 
genome alteration; PGA).  We demonstrate that c-MYC gain alone, or 
combined c-MYC gain and PTEN loss, were increasingly prognostic for 
relapse on multivariable analyses (hazard ratios (HR) of 2.58/p=0.005 
and 3.21/p=0.0004; respectively).  Other loci were also prognostic for 
biochemical disease-free relapse (StAR: HR=2.84, 95% CI: 1.44-5.61, 
p=0.00269; HSD17B2: HR=1.97, 95% CI: 1.06-3.64, p=0.031 and, 
NKX3.1 haploinsufficiency was associated with bRFR when tested 
alone (HR=3.05, 95% CI:1.46-6.39, p=0.0030) or when combined with 
c-MYC gain (HR=3.88, 95% CI:1.78-8.49, p=0.00067)). All aCGH hits 
were also positive for outcome on multivariate analyses in prostate 
cancer surgery patients. 
Finally, a novel genetics-based signature has been developed that is 
independently prognostic. Our multidisciplinary group has also shown 
that both increased genetic instability and intra-glandular hypoxia 
predicts for poor outcome in intermediate risk prostate cancer. 
Additionally, when paired with information from hypoxia measure-
ments in the same patients, a combination of genetic and hypoxic 
biomarkers is more prognostic that either alone. 
Our data from primary human specimens suggest that triaging patients 
by the use of personalized genetics may allow for better use of sys-
temic therapies to target sub-clinical metastases or locally recurrent 
disease. The development and utility of such genetics-based tests and 
use within novel clincal trials with curative intent will be discussed. 
This personalized approach will improve clinical outcome in more than 
20,000 patients worldwide who currently fail precision radiotherapy 
and surgery despite having localized disease. 
 
 SYMPOSIUM: THE BIOLOGY OF OLIGO-METASTATIC 
DISEASE  
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Stereotactic body radiotherapy has previously been successfully used 
in the treatment of metastatic lesions located in the lung and liver. It 
could also be considered as a curative option for patients suffering 
from oligometastases. In our Department, the feasibility, efficacy, 
and toxicity of SBRT as been evaluated for treatment of unresectable 
hepatic or lung metastases regardless of their primary tumor site for 
patients with a history of agressive systemic chemotherapy. Between 
July 2007 and June 2010, 90 patients were prospectively enrolled in 
this observational study and treated with the SBRT for hepatic or 
pulmonary metastatic lesions. A total of 113 liver and 26 lung metas-
tatic lesions in 52 men (58%) and 38 women (42%) were treated. Local 
control rates at 1 and 2 years were 84.5% and 66.1%, respectively. 
Two-year overall survival rate was 70% (95% CI: 55–81%) and the 1 and 
2-year disease-free survival rates were 27% (95% CI: 18–37%) and 10% 
(95% CI: 4–20%).  
Such results suggest that SBRT could be an effective treatment option 
extending patients’ life span with good quality of life following treat-
ment. Overall survival is comparable with other available techniques. 
Treatment is well tolerated with very low toxicity. This treatment 
modality appears to be more effective when used prior to the initia-
tion of systemic treatment regimens,which can be an important 
finding to be tested further. It could represent an interesting treat-
ment option for oligometastatic patients not amenable to surgery, 
even when patients had been heavily pre-treated with chemotherapy. 
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Different biological aspects have to be considered when estimating 
the effect of radiotherapy on oligometastases: 
1) In contrast to current systemic treatments, radiotherapy has a high 
potential to inactivate cancer stem cells that are able to cause tu-
mour recurrences. In limited disease stages or, in some cancers, 
limited metastases stages, this is the basis of the curative potential of 
radiotherapy and also of complete inactivation of macroscopic metas-
tases. 
2) Size of the metastases is predictive for in-field-control. This corre-
lation exists in primary tumours as well as in metastases and reflects 
the impact of the higher number of cancer stem cells to be inacti-
vated in larger tumours and maybe also higher impact of other resis-
tance factors like hypoxia. 
3) Metastases develop through vascular spread of tumour cells, i.e. 
oligometastases always bear a high risk of later development of 
further metastases. The time to further disease Progression appears to 
be longest with a longer time interval between treatment of the 
primary tumour and development of oligometastases. While this is 
known for a long time, approaches to biologically characterize tu-
mours with low versus high potential for multi- or oligometastatic 
spread are only recently developed. 
4) Single or oligometastases are often treated using hypofractionated-
accelerated radiation treatment schedules, i.e. applying high doses 
per fraction and higher doses per week as compared to conventionally 
fractionated radiotherapy schedules. These schedules lead to a higher 
biological efficacy in the tumour, but also in irradiated normal organs. 
Thus, for application of high radiation doses, from biological reasons 
the use of high precision radiotherapy techniques is mandatory to take 
advantage from the volume-effects in normal tissues that can com-
pensate for the disadvantage of the high doses per fraction. 
The talk will give an overview on biological considerations for high-
dose radiotherapy of oligometastases and on open questions for 
further improvement of treatment. 
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Two models of circulating tumor cell (CTC) dynamics have been 
proposed to explain the phenomenon of tumor ’self-seeding’, whereby 
CTCs repopulate the primary tumor and accelerate growth: Primary 
Seeding, where cells from a primary tumor shed into the vasculature 
and return back to the primary themselves; and Secondary Seeding, 
where cells from the primary first colonize a secondary tissue which 
then sheds cells into the vasculature returning to the primary. The-
setwo models are difficult to distinguish experimentally, yet the 
differences between them is of great importance to both our under-
standing of the metastatic process and also for designing methods of 
intervention. Therefore we developed a mathematical model to test 
the relative likelihood of these two phenomena and show that Sec-
ondary Seeding is several orders of magnitude more likely than Prima-
ry seeding. We suggest how this difference could effect tumor evolu-
tion, progression and therapy and several possible methods of experi-
mental validation.  
   
 SYMPOSIUM: PET QUANTIFICATION  
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The role of positron emission tomography (PET) in radiation oncology 
continues to expand beyond the realm of preliminary diagnosis, where 
FDG PET has directly impacted disease staging in more than 30 % of 
cancer patients. Radiation oncology clinicians and researchers seek to 
incorporate PET more objectively into radiotherapy (RT) planning and 
therapeutic response assessment by leveraging its high sensitivity, 
tracer specificity, and capacity for absolute quantification. As PET 
evolves from a qualitative diagnostic tool to a quantitative theragnos-
tic tool, a growing number of clinical trials are evaluating the efficacy 
of personalized and adaptive RT regimens based on the spatiotempor-
al dynamics of heterogeneous PET uptake. 
However, complex quantitative tasks require the estimation and 
mitigation of many PET uncertainties. They arise from physical, 
technical, and biological factors that impact PET lesion signal (con-
trast) relative to noise, system spatial resolution,and reproducibility. 
This talk will review uncertainties that determine confidence intervals 
within which we can trust PET in the context of RT target definition 
and RT response assessment. In particular, physical uncertainties 
arising from the image formation process, technical uncertainties 
from pre- and post-imaging processes, and biological uncertainties 
from patient-specific tracer kinetics and therapy-induced dynamics 
will be presented. 
The level of trust in PET can be linked to the incorporation of uncer-
tainties into quantification processes. For example, test-retest studies 
can establish achievable degrees of precision when assessing longitu-
dinal changes in PET metrics. While some uncertainties are mitigated 
through standardization of imaging procedures within and between 
institutions, others pose formidable challenges that require innovative 
technologies and methodologies. Such challenges motivate the need 
for improved PET quantification and seamless integration into RT 
planning through multidisciplinary collaboration. 
 
  
Example workflow of PET quantification tasks in radiation oncolo-
gy. From tumor biology at the cellular scale to PET-based target 
definition and therapy response assessment at the image voxel scale, 
quantitative tasks carry uncertainties that must be estimated and 
mitigated. This talk will focus on uncertainties in Steps 1 and 2 in the 
context of their impact on downstream components.  
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PET is a functional and molecular imaging modality allowing to meas-
ure (biological) tumor characteristics quantitatively. The most com-
monly used parameter to quantify tumor tracer uptake is the so-called 
maximum standardized uptake value (SUVmax). Yet, various other 
parameters may be of interest. Metabolically active tumor volume 
(MATV), total tumor burden (sum of MATV over all lesions) or total 
lesion glycolysis (TLG, product of MATV and SUV) have shown value as 
predictive or prognostic factor. Beyond measuring glucose consump-
tion with 18F-FDG there is increased interest in the use of other trac-
ers and/or labeled drugs. Proliferation measured with 18F-FLT or 
hypoxia measured with e.g. 18F-AZA can be of particular interest in a 
radiotherapy setting. Specific imaging procedure optimizations may be 
required when using non-FDG PET tracers. In addition, use of simpli-
fied (static) image procedures and data analysis methods may need to 
be validated against full kinetic analysis to determine use of e.g. SUV 
as appropriate surrogate for the physiological parameter of interest. 
Full kinetic analysis can then be helpful to determine which simplified 
quantitative measure is providing the most accurate and robust 
results. For example, tumor to blood ratios may be more suitable than 
SUV measures and SUV normalized by body weight may be suboptimal 
compared to other normalizations, such as body surface area, depend-
ing on the biodistribution of the tracer. 
All quantitative PET measures, however, depend largely on the way 
PET images are collected, reconstructed and analyzed. Moreover, new 
image reconstruction technologies, that include resolution recovery, 
can improved image resolution and contrast recovery, but at the same 
time suffer from increased upward bias when PET images are quanti-
fied using the maximum standardized uptake value. Consequently, 
when implementing new PET imaging technologies one should also 
adapt data analysis procedures in order to obtain and maintain robust 
quantitative data. 
When quantitative PET studies are performed as part of multicenter 
studies it is not only essential to optimize the PET imaging and data 
analysis procedure for the specific question to be addressed, but also 
to make sure that studies are performed in a standardized manner and 
that all scanner performances are harmonized to a common standard. 
There are various organizations that offer scanner validation or accre-
ditation (QC) programs. Most of these programs recognize the need 
not only to verify the basic calibration and uniformity of the PET 
